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Abstract
Recent technologies have made it possible to efficiently identify several broadly cross-neutralizing
antibodies against the hemagglutinin of influenza A virus. With these advances comes a potential
new age in influenza virus vaccine development and the possibility of effective, therapeutic
immunotherapy.
Introduction and context
Influenza A virus is the cause of yearly seasonal
epidemics and occasional pandemics with devastating
effects. A current obstacle in the control of influenza is
the lack of a vaccine that provides long lasting immunity
from year to year, and that ideally confers protection in a
pandemic situation. The challenge lies in the ability of
influenza virus to antigenically change at a rapid pace,
either by gradually accumulating mutations (antigenic
drift) or by genetic reassortment via the exchange of viral
genome segments (antigenic shift), thereby evading
immune detection. Currently, influenza A virus H1 and
H3 subtypes [based on the antigenicity of the viral
hemagglutinin (HA)] are circulating in humans, but
there are another 14 different HA subtypes circulating in
birds, which theoretically could initiate a new pandemic.
One logical approach to circumvent viral antigenic
changes is to identify epitopes that are broadly cross-
reactive among multiple influenza virus strains within a
subtype or even between virus subtypes, that is, to
overcome antigenic drift or antigenic shift. The feasibility
of this idea, however, has long been doubted. Given the
pivotal role of antibodies against the viral HA in
controlling influenza infection [1–4], the prevailing
belief has been that neutralizing antibodies targeting
influenza viruses are directed against variable antigenic
sites on the HA protein and are thus specific for a
particular strain. It is noteworthy, therefore, that recent
evidence challenges this dogma. Influenza antibodies
with cross-neutralizing properties can in fact be isolated
using available technologies and, moreover, they may
serve as a guide for vaccine design or as a source of
material for passive immunization therapy.
Major recent advances
An appealing technique in the hunt for broadly
neutralizing epitopes of influenza viruses is the screening
of combinatorial antibody libraries, either engineered
synthetically or derived from influenza virus-infected or
vaccinated individuals, for reactivity with various strains.
A combinatorial antibody library can represent the entire
diversity of the human antibody repertoire or, more
specifically, a complete history of an individual's
immunological response to a pathogen. These libraries
are, therefore, a rich source of fully human, monoclonal
antibodies that potentially have therapeutic properties.
By screening a combinatorial antibody library generated
from the bone marrow of survivors of H5N1 avian
influenza virus infections, Kashyap and colleagues [5]
successfully obtained more than 300 unique H5N1
specific monoclonal antibodies, as well as three anti-
bodies that neutralized both H5 and H1 subtypes of
influenza viruses. A distinct advantage of these library
approaches is the sheer number of antibodies produced
for screening. With this vast complexity comes the
opportunity to identify those rare antibodies that may
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have high affinity for a particular antigen or other unique
features, for example, those that may target an epitope
outside of the major antigenic sites of HA or even in
another viral protein. Moreover, comparison of neutra-
lizing versus non-neutralizing antibodies, as well as
sequence analysis of these library members, could
provide information on the physical interactions that
govern virus neutralization.
Aside from combinatorial libraries, technologies that
allow the efficient cloning of antibodies directly from
humans supply an additional source of novel antibodies
with cross-neutralizing or other favorable properties.
Simmons et al. [4] cloned B-cell lines secreting neutraliz-
ing antibodies against H5N1 viruses from H5N1-
infected survivors, and some of these antibodies could
neutralize multiple H5N1 strains. Wrammert et al. [6]
reported the cloning of high-affinity monoclonal anti-
bodies from individuals following influenza vaccination.
Antibodies specific for each of the three component
vaccine strains could be rapidly isolated from patients
within 7 days of vaccination. In a subsequent study, it
was demonstrated that influenza neutralizing antibodies
could be isolated from the circulating B cells of 1918
influenza pandemic survivors [7]. Among these mono-
clonal antibodies was at least one that cross-neutralized a
highly divergent H1N1 virus from 1977. In addition,
further analysis of the antibody responses in these 1918
survivors, as well as in survivors of more recent
pandemics, may provide insights into the requirements
for a successful immune response against pandemic
influenza and a potential source of monoclonal anti-
body therapy.
Structural information on different HA proteins comple-
ments antibody screening for identifying novel, cross-
reactive neutralization targets. Crystal structures are
available for several HA subtypes, including H1, H3,
and H5 HAs, and these structures can be compared to
guide the rational targeting of epitopes that may be cross-
reactive [8–14]. Between subtypes, this may be more
feasible for the H1 and H5 HAs, which have higher
homology, both at the amino acid and the structural
level, compared to H3 HAs [15]. Information can also be
garnered from studies examining how structure-based
modification of HA affects antigenicity. Yang and
colleagues [15] investigated mutations in the receptor
binding domain of an avian (H5) HA that altered its
specificity for particular sialic acid linkages, one of the
known determinants of influenza virus host tropism.
After immunization of mice with these mutants, the
group isolated monoclonal antibodies capable of neu-
tralizing lentiviral particles bearing these HA variants.
These data suggest that it may be possible to predict
epitopes likely to react with emerging influenza strains
based on HA structure and receptor specificity. Notably,
the neutralizing antibodies that were isolated in this
study targeted epitopes within the receptor-binding
domain that were adjacent to, but outside of, the
major antigenic sites of HA.
Future directions
Technologies that utilize combinatorial libraries and
allow the rapid cloning of antibodies from humans,
combined with structural analysis of HA variants,
provide methods to identify novel, cross-reactive epi-
topes in influenza A virus. Potentially, these approaches
will also yield invaluable information on the chemistry
of antibody binding to epitopes, the requirements for
virus neutralization, and the determinants of an effective
vaccine. Characterization of the HA epitopes recognized
by broadly neutralizing antibodies might provide
information for the design of novel vaccines presenting
only these epitopes. A vaccine that protects individuals
from various strains within a single subtype would
already be an improvement over the current, yearly
vaccines. However, an ideal approach with the threat of
an impending pandemic is one that protects or can be
used as therapy across subtypes and emerging strains.
Recent studies suggest that identification of anti-influ-
enza virus monoclonal antibodies with cross-reactive
properties is now within reach. However, a number of
important questions remain regarding the application of
these techniques in the clinical setting. For example, how
can we design an immunogenic vaccine that presents
influenza virus cross-reactive epitopes and provides high
levels of protection against infection? Furthermore, how
quickly will these sites mutate in the presence of selective
pressure generated by vaccination? Also, would mono-
clonal antibody therapy reduce morbidity and mortality
in infected individuals? These are among the many
questions that are worthy of, and will surely be the
subject of, future research.
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